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Background: Many people with dementia experience anxiety, which can lead to decreased independence,
relationship difficulties and increased admittance to care homes. Anxiety is often treated with antipsychotic
medication, which has limited efficacy and serious side effects. Cognitive behavioural therapy (CBT) is widely
used to treat anxiety in a range of populations, yet no RCTs on CBT for anxiety in dementia exist. This study aims
to develop a CBT for anxiety in dementia manual and to determine its feasibility in a pilot RCT.
Methods/design: Phase I involves the development of a CBT for anxiety in dementia manual, through a process of
(1) focus groups, (2) comprehensive literature reviews, (3) expert consultation, (4) a consensus conference and (5)
field testing. Phase II involves the evaluation of the manual with 50 participants with mild to moderate dementia
and anxiety (and their carers) in a pilot, two-armed RCT. Participants will receive either ten sessions of CBT or
treatment as usual. Primary outcome measures are anxiety and costs. Secondary outcome measures are participant
quality of life, behavioural disturbance, cognition, depression, mood and perceived relationship with the carer, and
carer mood and perceived relationship with the person with dementia. Measures will be administered at baseline,
15 weeks and 6 months. Approximately 12 qualitative interviews will be used to gather service-users' perspectives
on the intervention.
Discussion: This study aims to determine the feasibility of CBT for people with anxiety and dementia and provide
data on the effect size of the intervention in order to conduct a power analysis for a definitive RCT. The manual will
be revised according to qualitative and quantitative findings. Its publication will enable its availability throughout
the NHS and beyond.
Trial registration: ISRCTN64806852
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Randomised controlled trial (RCT)Background
In the UK, over 700,000 older people have dementia,
placing an enormous strain on public services and family
carers [1]. There are limits in the effectiveness and use
of dementia medication [2] and in recent years there has
been an increase in the development of psychosocial
treatments for dementia [3]. Anxiety is common in* Correspondence: a.spector@ucl.ac.uk
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reproduction in any medium, provided the ordementia, with prevalence estimated from 5-21% for
anxiety disorders and up to 71% for anxiety symptoms
[4]. In addition to excessive worries and fears, anxiety
may physically manifest as agitation, motor restlessness,
day/night disturbance and aggression. It has been asso-
ciated with high physical dependency and problems in
the patient/carer relationship [5], decreased independ-
ence and limitations in activities of daily living [6],
increased behavioural problems [7] and increased admis-
sions to nursing care [8]. Anxiety is often treated with
antipsychotic medication, which has limited efficacy andl Ltd. This is an Open Access article distributed under the terms of the Creative
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stroke and cognitive deterioration [9].
Cognitive behaviour therapy (CBT) [10] focuses on the
interplay among people’s thoughts, feelings and behav-
iour. It primarily focuses on the here and now, is highly
collaborative and aims to identify personalised, time-
limited goals and strategies that are put into practice
between sessions (“homework”). There is robust evi-
dence that CBT is an effective first-line strategy for anx-
iety in general adult populations [2] and for cognitively
intact older people [11]. CBT has been widely adopted
by the NHS, for example ‘Improving Access to Psycho-
logical Therapies’ (IAPT) [12] aims to support primary
care trusts in implementing CBT for depression and
anxiety in people of 'working age'.
People with dementia have diminished cognitive
resources, but there is evidence that they can learn and
develop skills, even when moderately cognitively
impaired [13]. This suggests that CBT in an adapted
form could be used with this client group, as it has been
in other impaired populations such as those with learn-
ing disabilities [14]. There is evidence for the effective-
ness of CBT for depression in dementia, primarily
through case studies and an RCT by Teri et al. [7].
There are only four small studies examining CBT for
anxiety in dementia. Kipling et al. [15] found changes in
behaviour, cognition and mood in a group of three
people. Koder [16] and Kraus et al. [17] each described
two individual cases and found clinically meaningful
reductions in anxiety, plus improved mood and partici-
pation in pleasurable activities [17], and reduction in
alcohol intake and night awakenings [16]. Paukert et al.
[18] developed Peaceful Mind, a CBT intervention for
anxiety and dementia, finding reductions in anxiety,
depression and carer distress in an open trial containing
eight individuals. All four studies suggest that CBT in
people with dementia is feasible and concluded that
larger trials are now needed, yet there are no published
RCTs in CBT for anxiety for dementia.
There will be two phases to this trial, which corres-
pond to phase I and II of the MRC’s guidelines for devel-
oping a complex intervention and assessing feasibility
[19]. The key aims are:
(1) To develop a CBT intervention manual.
(2) To assess the feasibility of the intervention
through a single-blind, pilot RCT on CBT versus
treatment as usual (TAU) for people with dementia
and their carers. This will include an assessment
of acceptability, compliance, recruitment
and retention.
(3) To conduct qualitative interviews with participants,
assessing the acceptability of the treatment and
examining whether changes generalised.Method
Phase I: Development phase
This phase consisted of four stages:
1. Focus groups: We conducted nine focus groups with
service-users (people with dementia, family carers
and staff groups) on causes and management of
anxiety [20]. Emerging themes included coming to
terms with the diagnosis and loss of skills as causes,
and person-centred care, memory aids and
medication as a last resort in terms of management.
2. Comprehensive literature reviews: We have published
the protocol for a Cochrane systematic review on
psychosocial interventions for anxiety and depression
in dementia [21] and are currently writing the full
review. The findings of relevant studies identified in
the Cochrane review along with the focus group
findings and outcomes of a comprehensive review
of the literature on CBT for anxiety (in general
populations and with older adults) were used to
adapt the best features and identify key techniques
and potential adaptations and generate version 1
of the manual.
3. Expert consultation: Version 1 of the manual was
sent to three experts in dementia and/or CBT and
revised according to their comments, generating
version 2.
4. Consensus process: A Delphi process [22] is
commonly used to reach consensus when defining
new interventions in health service research.
We used a modified Delphi process, outlining a
set number of cycles at the outset. Version 2 was
brought to an advisory panel of 30 multidisciplinary
experts (psychologists, psychiatrists, CBT therapists,
carers, admiral nurses and occupational therapists)
at a half-day consensus conference. Different parts
of the manual were discussed by small groups, with
the aim of generating feedback and suggestions for
modifications. Amendments following the consensus
conference generated version 3 of the manual.
5. Field testing: Version 3 was field tested with three
people with dementia and their carers, which
generated information about modifications needed
to improve its feasibility and relevance in practice.
These data were used to develop version 4 of the
manual, which was sent back to an expert panel for
further comments. Further modifications resulted
in version 5, to be used for the trial.
Phase 11: Intervention phase
Design
The design is a single-blind, multicentre, pilot RCT of
CBT plus treatment as usual (TAU) versus TAU for
people with dementia. Patient-carer dyads will be
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have been done in this area, we were unable to estimate
the likely effect size of this intervention. We will recruit
50 participants with power set at 80%, p = 0.05. This will
be adequate to detect an effect size of 0.8 or above.
An objective of this study is to provide data on the actual
effect size of the intervention in order to do a power ana-
lysis for a definitive RCT. Figure 1 shows the trial design.
Participants
Fifty participants and their carers will be recruited
through North East London Foundation Trust (NELFT)
and North Essex Partnership NHS Foundation Trust
(NEPFT). Recruitment will be through memory services,
community mental health teams, admiral nursing teams
and outpatient referrals.
Inclusion criteria are:
1. Meet DSM-IV criteria for dementia in mild to
moderate range, Clinical Dementia Rating (CDR)
[23] score of 0.5, 1 or 2.
2. Clinical anxiety, as determined by a score of 11 or
above on the Rating Anxiety in Dementia scale
(RAID) [24].Figure 1 CBT for anxiety in people with dementia flow diagram.3. Living in the community.
4. The presence of a carer who is willing to participate
in the therapy.
5. An ability to understand and communicate
in English.
6. Willing to engage in therapy involving discussion
of thoughts and feelings.
Exclusion criteria are:
1. Co-morbid psychiatric disorder (e.g. psychosis) or
challenging behaviour (e.g. severe agitation) likely
to prevent engagement in therapy.
2. Presence of a learning disability or severe physical
illness that could impact on participation.
Ethical considerations
Ethical approval was obtained through the East London
3 Research Ethics Committee (ref. no. 10/H0701/124).
Informed consent will be sought from participants and
their carers, using current guidance from the British
Psychological Society on evaluation of capacity. Partici-
pants may withdraw from the trial at any time without
giving a reason. The withdrawal of the participant from
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treatments or services.
All information disclosed in the study will be kept
confidential, and participants will not be identifiable in
any material published as part of the study in any way.
All data are stored without any identifying details under
secure conditions and all tapes will be destroyed at the
end of the trial. In line with Standard Operating Proce-
dures for the study, the reporting of Serious Adverse
Events will be made to the Chief Investigator. The Chief
Investigator will then inform the Research & Develop-
ment Manager and Trust Governance Manager. Local
policy and procedures will be followed for reporting and
investigating serious untoward incidents.
Randomisation
Randomisation will be conducted by telephoning an in-
dependent administrator within PRIMENT Clinical
Trials Unit after the participant/carer has provided
informed consent and baseline data. The randomisation
schedule is being developed by an independent statisti-
cian in PRIMENT, and blocking will be employed (with
block sizes varying between 4 and 6) to help ensure
equal numbers in the intervention and control arms.
Interventions
CBT plus TAU: The patient-carer dyads will participate
in 10 weekly sessions, each lasting 1 h hour. This number
was determined on the basis of the published literature,
the team’s experience and patient and carer feedback.
The manual is divided into four phases. Phase 1
involves assessment and formulation. Key aims are to
build a collaborative relationship, socialisation to the
CBT model, identifying goals and establishing the
involvement of the carer. The carer’s role is to support
the person with dementia in implementing strategies, for
example applying what has been discussed during ses-
sions in everyday life. Their involvement could range
from very little (e.g. attending brief parts of some ses-
sions) to being present at all times. Phase 2 involves the
application of change processes, which the therapist will
adapt according to the needs and strengths of the indi-
vidual. These include identifying and practicing strategies
for feeling safe, identifying and challenging unhelpful
cognitions, ‘realistic negative automatic thoughts’, calming
thoughts (on cue cards) and behavioural experiments.
Phase 3 works on ending the therapy and developing a
blueprint for the future. This includes reviewing and
consolidating learned skills, integration of skills into
everyday life and considering the future involvement of
carers and others.
Sessions will cover themes and broad ideas, but there
will be specific guidelines on how to adapt them to suitthe needs of individuals. For example, the degree to
which ‘cognitive’ and ‘behavioural’ elements are used will
vary, with higher functioning participants being more
able to access the ‘cognitive’ and a greater emphasis on
behavioural aspects with the more impaired.
For some, sessions may need to be shortened or breaks
may be required to maximise attention.
Telephone contact will be offered between sessions to
answer questions and encourage ongoing work, should it
be required. Sessions will be delivered by clinical or
counselling psychologists, with experience of working
with people with dementia. They will be given regular
clinical supervision by a senior old age clinical psycholo-
gist with specialist CBT training.
Treatment as usual (TAU): This is defined as the
standard treatment available to people with anxiety and
dementia, which is most likely to include medication or
no treatment.
Outcome measures
All outcome measures will be administered by the main
research assistant, blind to group allocation, at week 1
(baseline), week 15 (follow-up 1) and 6 months (follow-
up 2). Fifteen weeks for follow-up 1 was determined by
the field-testing phase, which suggested that it takes an
average of 15 weeks to complete a ten-session interven-
tion because of factors such as randomisation time, ill-
ness and holiday. Demographics and general information
will be collected including age, gender, ethnic group, use
of medication (including anxiolytics and cholinesterase
inhibitors), treatment preference and participation in
other activities. The Clinical Dementia Rating (CDR)
[23] will be used to provide a global rating of dementia
severity as part of the general background information.
Primary outcome measures
1. Rating Anxiety in Dementia (RAID) [24]. This rates
signs and symptoms of anxiety using interviews with
carers and people with dementia. There are 18
questions in four categories: worry, apprehension,
vigilance, motor tension and autonomic
hypersensitivity. A score of 11 or above indicates
significant clinical anxiety. It has good inter-rater and
test-retest reliability, is sensitive to change and
correlates with quality of life [25].
2. Clinical Services Receipt Inventory (CSRI) [26]. A
tool that collects information about the interviewee’s
use of health and social care services,
accommodation and living situations, income,
employment and benefits, and any changes that may
be incurred in the receipt of these services (after the
therapy).
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3.Mood: Hospital Anxiety and Depression Scale
(HADS) [27]. The HADS is a widely used measure of
anxiety and depression validated for all age groups.
4.Quality of life (QOL): Quality of Life-Alzheimer’s
Disease (QOL-AD) [28]. This is a self-report measure
for the person and their carer, with 13 items covering
domains including physical health, energy, friends
and fun. It has excellent inter-rater reliability and
internal consistency, and good content, criterion
and construct validity.
5. Behavioural disturbance: Neuropsychiatric Inventory
(NPI) [29]. This assesses ten areas including
delusions, hallucinations, dysphoria and agitation/
aggression. Content and concurrent validity,
inter-rater and test-retest reliability and internal
consistency are all good.
6. Cognitive function: Mini-Mental State Examination
(MMSE) [30]. This is an internationally recognised,
11-item set of simple tasks presented to the
participant including orientation to time and place,
attention, recall, language and visual construction.
It has a maximum score of 30 points, with 24 or less
suggesting cognitive impairment. Reliability and
validity are satisfactory.
7.Depression: Cornell Scale for Depression in
Dementia [31]. This rates depression in five
categories including mood-related signs, behavioural
disturbance and ideational disturbance, using
information from interviews with staff and
participants. Good reliability and validity have
been demonstrated.
8. Person-carer relationship: Quality of Caregiver and
Patient Relationship (QCPR) [32]. This is a 14-item
scale measuring relationship quality including the
level of criticism and level of warmth, rated by
both the person and their carer. Good reliability
and validity have been demonstrated.
9. Carer mood: Hospital Anxiety and Depression
Scale (HADS) [27].Qualitative interviews
After follow-up 1, 12 patient-carer dyads who received
CBT will be invited to take part in qualitative interviews,
led by another research assistant (to ensure blindness to
treatment) and lasting approximately 1 hour. Issues
addressed will include experiences of the sessions, views
on themes and techniques, and benefits/changes identi-
fied in everyday life. Interviews will be audio recorded
and transcribed. Framework analysis [33] will be used to
extract themes and draw conclusions.Treatment implementation strategies
Treatment implementation (TI) strategies are recom-
mended to ensure that treatment has been delivered,
received and enacted as intended [34]. We will employ
several methods to monitor treatment delivery and re-
ceipt: (1) the training and manual; (2) an adherence
checklist devised in the manual, developed for the
purpose of the study; (3) by audio recording all sessions,
of which a random sample will be checked by GC for ad-
herence to the manual. Treatment receipt and enactment
will also be explored through qualitative interviews.Statistical analysis
As this is a pilot trial, our main aims in evaluation will
be to record response to recruitment, acceptability of
randomisation, retention in therapy, attrition, prescribing
of anxiolytics, any negative effects, extent/distribution of
missing data and basic costs. We will conduct explora-
tory statistical analyses as our sample size will limit
definitive conclusions. Data will be analysed by SPSSv16
using 'intention to treat'. Differences in outcomes be-
tween the two arms of the RCT over time will be mod-
elled using generalised estimating equations, taking into
account potential clustering due to using several thera-
pists. We will also conduct exploratory analyses of fac-
tors predicting treatment outcome such as anxiolytic
medication, age, dementia severity, treatment preference
and number of sessions received. The confidence inter-
vals around the effect size for the primary outcome, anx-
iety, will help us to estimate the sample size required for
a full-scale trial.Discussion
The NHS predominantly offers either nothing (as anx-
iety frequently goes unrecognised) or medication for
anxiety in dementia, even though NHS guidelines sug-
gest that it should only be used if there is severe distress
or risk [2]. We will produce a CBT training manual for
staff, which we will make available online. This will en-
able its widespread use by NHS professionals. This trial
should prepare the ground for a definitive RCT, with
CBT potentially offering an alternative to medication for
many people. CBT could lead to significant and general-
ised benefits, reducing excess disability and social exclu-
sion, by improving cognitive and behavioural functioning
and reducing carer burden. Costs to the NHS might be
reduced through decreased use of medication, services
(such as GP visits) and reduced nursing home placement.
The National Dementia Strategy [35] highlights (1) the
need for early treatment and support around the time of
diagnosis and (2) keeping people at home for longer.
CBT could provide the emotional support and skill
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extreme anxiety, and improve the home situation by
offering carers strategies to help the person at difficult
times and across situations. Ultimately, it will allow
patients the option of a first-line psychological interven-
tion, the norm in general clinical practice.
Trial status
The trial commenced in November 2010 and will end in
April 2013. It is currently half way through the recruit-
ment phase, with 25 of the 50 participants recruited.
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